What the company pays Pourhassan is after all our money Misiu.

It should not be spent foolishly on his outlandish salary at a time when the company is running on fumes.

I truly hopes Pourhassan proves me wrong on his competence, and some of his promises regarding non-dilutive financing and partnerships, among other things, eventually turn out to be true.

However, until that happens, Pourhassan's compensation should reflect that befitting a 40 cent clinical stage biopharma that has been forced to live off of dilutive Paulson financing for many years.

And would it hurt Pourhassan to invest some of his $1.5M compensation in company stock, along with us shareholders?

While I believe the company would do much better under the tutelage of a more experienced and competent CEO, while we are stuck with Pourhassan, he should at least be paid a reasonable salary, which $1.5M clearly is not.

Thank you for your continued input, and words of medical wisdom.

LM